ESMO 2024 – Nuvalent looks beyond its late-line Alkove
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.
Triple data take Nuvalent's market cap above $3bn
After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.
World Lung 2023 preview – Astra’s Tagrisso showdown
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
